[Articles] Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial
Compared with STAS, ITAS plus zoledronic acid was more effective for treatment of prostate cancers with a Gleason score of 8–10, and ITAS alone was effective for tumours with a Gleason score of 7 or lower. Nevertheless, these findings are based on secondary endpoint data and post-hoc analyses and must be regarded cautiously. Long- term follow-up is necessary, as is external validation of the interaction between zoledronic acid and Gleason score. STAS plus zoledronic acid can be ruled out as a potential therapeutic option.
Source: The Lancet Oncology - Category: Cancer & Oncology Authors: James W Denham, David Joseph, David S Lamb, Nigel A Spry, Gillian Duchesne, John Matthews, Chris Atkinson, Keen-Hun Tai, David Christie, Lizbeth Kenny, Sandra Turner, Nirdosh Kumar Gogna, Terry Diamond, Brett Delahunt, Christopher Oldmeadow, John Attia, A Tags: Articles Source Type: research